Matteo Nicola Dario Di Minno, Pasquale Ambrosino, Veronika Myasoedova*, Manuela Amato, Itala Ventre, Elena Tremoli and Alessandro Di Minno Pages 1125 - 1131 ( 7 )
In the absence of definite guidelines in the area, we have carried a systemic review to provide a thorough overview concerning the efficacy and safety of recombinant activated factor VII (rFVIIa, NovoSeven®, Novo Nordisk A/S, Bagsværd, Denmark) in patients with Glanzmann’s thrombasthenia (GT) and FVII deficiency, undergoing surgical procedures. PubMed, Web of Science, Scopus and EMBASE databases was employed for the search. Three multicenter registries were identified: the Glanzmann’s Thrombasthenia Registry (GTR), the Seven Treatment Evaluation Registry (STER), and a German post-marketing surveillance registry (the WIRK study). In addition, data from 10 case-series and/or single-center experiences have been summarized. We have found that the following; perioperatively, the hemostatic effectiveness of rFVIIa was high in GT patients and in those with FVII deficiency undergoing both minor and major surgical procedures. Moreover, in all studies, rFVIIa was well tolerated. Thus, the current evidence shows an optimal perioperative safety/efficacy profile of rFVIIa in the setting of these rare bleeding disorders, and provides the rationale for further studies aimed at evaluating the optimal perioperative anti-hemorrhagic prophylaxis with rFVIIa in GT and in FVII deficient patients.
Glanzmann's thrombasthenia, factor VII deficiency, recombinant activated factor VII, NovoSeven.
Department of Advanced Biomedical Sciences, Division of Cardiology, Federico II University, Naples, Department of Clinical Medicine and Surgery, Federico II University, Naples, Unit of Atherosclerosis Prevention, Centro Cardiologico Monzino IRCCS, Via Carlo Parea 4, 20138, Milan, Centro Cardiologico Monzino, IRCCS, Milan, Department of Clinical Medicine and Surgery, Federico II University, Naples, Centro Cardiologico Monzino, IRCCS, Milan, Centro Cardiologico Monzino, IRCCS, Milan